Trademark applications and grants for Idec Pharmaceuticals Corp. Idec Pharmaceuticals Corp has 30 trademark applications. The latest application filed is for "SOLIGENT"
Patent Application | Date |
---|---|
THERAPEUTIC APPLICATION OF CHIMERIC AND RADIOLABELLED ANTIBODIES TO HUMAN B LYMPHOCYTE RESTRICTED DIFFERENTIATION ANTIGEN FOR TREATMENT OF B CELL LYMPHOMA 20080089893 - 09/911703 Anderson; Darrell R. ;   et al. | 2008-04-17 |
Treatment of B-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combination 20050112060 - 10/703669 White, Christine | 2005-05-26 |
Compositions and methods for treating cancer using IGSF9 and LIV-1 20040258616 - 10/764604 McLachlan, Karen ;   et al. | 2004-12-23 |
Use of chimeric anti-CD20 antibody as in vitro or in vivo purging agent in patients receiving BMT or PBSC transplant 20040213784 - 10/850712 Grillo-Lopez, Antonio J. ;   et al. | 2004-10-28 |
Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof 20040005323 - 10/384356 Brams, Peter | 2004-01-08 |
SEC | 0000833923 | IDEC PHARMACEUTICALS CORP |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.